enrolment in basic sciences, and said that the decaying university system "needs upgrading in a massive way".
Singh was most troubled, he said, by "the decline in the standards of our research work in universities and even in advanced research institutes". For example, the return on billions of rupees invested in alternative energy sources was inadequate. "Be it [hydropower], thermal or nuclear power, we have to improve the productivity of investments already made." To raise quality, Singh warned that he may submit India's research labs to international peer review. This is the first time that Singh has publicly criticized Indian science. His comments were apparently provoked by briefings from his science adviser, the distinguished chemist C. N. R. Rao, indicating that India publishes only 2.7% of the world's science papers (compared with China's 6%) and describing the flight of talent In a direct but possibly futile challenge to the only veto of George Bush's presidency, the US Congress is expected to pass a bill for a second time that would dramatically expand researchers' access to human embryonic stem-cell lines. As Nature went to press, a vote in the House of Representatives was expected on 11 January, with the Senate likely to act on an identical measure within a few weeks.
The bill would allow federal funds to be used for research on stem-cell lines derived from surplus embryos at fertility clinics and otherwise slated for destruction. The embryos would have to be donated with informed consent and without payment or other inducements.
The California-based Rand Corporation estimated in 2003 that about 11,000 of the roughly 400,000 embryos stored at US fertility clinics at that time were available for research, from which it should be possible to derive up to 275 cell lines (D. I. Hoffman et al. Fertil. Steril. 79, 1063 -1069 2003) . The study's lead author, David Hoffman of IVF Florida Reproductive Associates in Margate, estimates that there may now be 10-15% more embryos in storage. Under current Bush administration policy, only around 20 stem-cell lines, all created before 9 August 2001, are available to federally funded researchers. These ageing lines are contaminated by having been grown on 'feeder' layers of mouse cells, making them impractical for developing human therapies.
Bush vetoed an identical bill last summer after both the House and Senate passed it, and the House failed by 51 votes to muster the twothirds majority needed to override his veto (see Nature 442, 335; 2006 back (Republican, Kansas) are not persuaded. "Right now, the private sector can spend all it wants on destructive human embryonic stemcell research, but such research is producing no human applications. There is simply no need to waste taxpayer dollars on this, " says Becky Ogilvie, a spokeswoman for Brownback.
Critics arguing that human embryonic stem-cell research is unnecessary were given ammunition on 7 January when Nature Biotechnology published a paper from a group led by Anthony Atala, director of the Institute for Regenerative Medicine at Wake Forest University in Winston-Salem, North Carolina. The researchers reported isolating stem cells from human amniotic fluid that can differentiate in vitro into many of the same major cell types as embryonic stem cells (P. De Coppi et al. Nature Biotechnol. doi:10.1038 2006) .
The study provides "yet another reason why there is no need to destroy young human embryos in order to obtain their biological parts", Brownback said in a statement. Supporters of the bill shot back. "This study…in no way replaces the need for expanding the [US government's] embryonic stem-cell policy, " Representative Michael Castle (Republican, Delaware), the other author of the House bill, said in his own statement.
Some supporters hope to amend the bill to make it more politically palatable to hesitant senators and more difficult for Bush to vetoperhaps by incorporating support for research on stem cells from adult sources.
But Bush has adamantly opposed expanded federal funding. DeGette notes that she asked to meet the president in November. Last week, she got a response from Bush's appointments secretary. It read: "The president would appreciate an opportunity to visit with you. Regrettably it will not be possible for us to arrange such a meeting at this time. "
Democratic senator Tom Harkin of Iowa, a leading supporter of the bill, vows to fight a second veto. On 4 January, the day the bill was introduced in the Senate, he said: "We will use every legislative means at our disposal to ensure that [the bill] is enacted into law. And it will happen during this Congress. "
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